Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
7 evidence topics · 3 sources
Substrate overload and lipotoxicity
“In defining pathogenic drivers of NAFL and NASH, a useful conceptual framework is that the liver’s capacity to handle the primary metabolic energy substrates, carbohydrates and fatty acids, is overwhelmed, leading to accumulation of toxic lipid species” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These metabolites induce hepatocellular stress, injury and death, leading to fibrogenesis and genomic instability that predispose to cirrhosis and hepatocellular carcinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When fatty acids are either supplied in excess or their disposal is impaired, they may serve as substrates for the generation of lipotoxic species that provoke ER stress and hepatocellular injury.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The presence and severity of NAFL and NASH are substantially determined by factors that govern the supply and disposition of fatty acids, diacylglycerols, ceramides, cholesterol, phospholipids, and other intrahepatic lipids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulin resistance and adipose tissue dysfunction
“Insulin resistance is nearly universal in patients with NAFLD and is present in the liver, adipose tissue, and muscle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adipose tissue insulin resistance is characterized by increased release of free fatty acids from adipocytes (lipolysis) in the fasting state” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A primary disease driver may be an oversupply of fat to adipocytes such that their ability to store triglyceride without inducing cell stress is exceeded, which activates inflammatory pathways and causes insulin resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic de novo lipogenesis and dietary sugars
“The metabolic mechanisms leading to NAFLD reflect an imbalance of energy metabolism in the liver: excess energy, mostly in the form of carbohydrates and fat, entering the liver relative to the ability of the liver to oxidize this energy to CO2 or export it as very-low-density lipoproteins (VLDLs) (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although excess consumption of any food can lead to development of NAFLD, mono- and disaccharides, especially fructose, sucrose, and high-fructose corn syrup, which is ubiquitous in processed foods, can activate programs of hepatic de novo lipogenesis that further exacerbate NAFLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Skeletal muscle insulin resistance, one of the earliest defects associated with metabolic syndrome and prediabetes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatocellular injury, inflammation, and macrophage activation
“Hepatocellular injury in NASH is characterized by endoplasmic reticulum (ER) stress” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“likely modulate the hepatocyte’s development of lipotoxic stress, injury and inflammation. The relative contribution of these defects in individuals with NASH is not clarified yet and likely varies among individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The response of the liver to lipotoxic injury includes activation and recruitment of resident macrophages, which further contributes to hepatocellular injury and stellate cell activation as part of a complex interplay among hepatic cell types.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additional factors such as hepatocyte uric acid production, exposure to products derived from the gut microbiome, and perhaps low hepatic magnesium levels, may also contribute to the NASH phenotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrogenesis through hepatic stellate cell activation
“The accumulation of extracellular matrix in the liver, which leads to progressive fibrosis, cirrhosis, portal HTN and liver failure, is the major cause of liver-related death in patients with NAFLD. Fibrogenesis is driven by signaling from stressed or injured hepatocytes and activated macrophages (Kupffer cells in the liver), leading to activation of resident hepatic stellate cells into myofibroblasts to produce matrix proteins faster than they are degraded” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Another NASH-specific pathway is through the PNPLA3-I148M variant’s effects directly on stellate cell fibrogenesis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic modifiers of hepatocyte lipid handling
“Although in some patients, the development and progression of NASH are driven by substrate overload and insulin resistance, in other patients, disease progression is heavily influenced by genetic factors impacting hepatocyte lipid handling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The I148M polymorphism of PNPLA3 impairs lipolysis of triglyceride in lipid droplets,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recently, lossof-function variants in HSD17B13, a gene that encodes an enzyme that also localizes to lipid droplets in hepatocytes, have been linked to protection against NASH, progressive fibrosis, and HCC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PPAR-mediated pathways as therapeutic targets: adipocyte insulin sensitivity, fatty acid oxidation, and inflammation
“improve adipocyte insulin sensitivity [eg, peroxisome proliferator-activated receptor (PPAR)γ ligands]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, peroxisome proliferator–activated receptor gamma (PPARγ) ligands (for example, pioglitazone), a specialized type of nuclear receptor ligand, enhance adipocyte storage of fat and improve NASH, albeit at the expense of increased peripheral fat stores and weight gain, as shown in clinical trials of these drugs in patients with type 2 diabetes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PPARα component increases fatty acid oxidation, whereas the PPARδ component has anti-inflammatory effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PPARγ ligands (for example, pioglitazone, a member of the family of thiazolidinedione class of drugs) have been studied in several trials and improve steatosis, inflammation and hepatocellular ballooning as well as hepatic fibrosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote